KemPharm (KMPH) Misses Q3 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equities rebound to close higher as surging Treasury yields recede
KemPharm, Inc. Reports Q3 2015 Results
November 12, 2015 4:17 PM ESTRecent Clinical Development Highlights:
Completed Human Abuse Liability Program for KP201/APAP, KemPharm's prodrug of hydrocodone (KP201), formulated in combination with acetaminophen (APAP) Reported positive results from second intranasal human abuse liability clinical trial of KP201/APAP Reported positive data demonstrating tamper-resistant properties of KP201/APAP Anticipate filing a new drug application (NDA) for KP201/APAP in Q4 2015Recent Product and Financial Highlights:
Initiated the development of an APAP-free formulation of KP201 as well as the development of an immediate release (IR) formulation of KemPharm's oxycodone prodrug,... MoreKemPharm, Inc. Reports Q3 2015 Results
November 12, 2015 4:17 PM ESTRecent Clinical Development Highlights:
Completed Human Abuse Liability Program for KP201/APAP, KemPharm's prodrug of hydrocodone (KP201), formulated in combination with acetaminophen (APAP) Reported positive results from second intranasal human abuse liability clinical trial of KP201/APAP Reported positive data demonstrating tamper-resistant properties of KP201/APAP Anticipate filing a new drug application (NDA) for KP201/APAP in Q4 2015Recent Product and Financial Highlights:
Initiated the development of an APAP-free formulation of KP201 as well as the development of an immediate release (IR) formulation of KemPharm's oxycodone prodrug,... More